SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001714899-20-000116
Filing Date
2020-11-05
Accepted
2020-11-05 16:14:07
Documents
16
Period of Report
2020-11-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K dnli-20201105.htm   iXBRL 8-K 40404
2 EX-99.1 ex991pressreleaseq32020.htm EX-99.1 94507
8 denali_txlogox011a.jpg GRAPHIC 65449
  Complete submission text file 0001714899-20-000116.txt   375328

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnli-20201105.xsd EX-101.SCH 2453
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT dnli-20201105_cal.xml EX-101.CAL 730
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT dnli-20201105_def.xml EX-101.DEF 1663
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnli-20201105_lab.xml EX-101.LAB 23970
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnli-20201105_pre.xml EX-101.PRE 12666
9 EXTRACTED XBRL INSTANCE DOCUMENT dnli-20201105_htm.xml XML 10834
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38311 | Film No.: 201290604
SIC: 2836 Biological Products, (No Diagnostic Substances)